Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting.

被引：1
|
作者：
Ravindranathan, Deepak
Liu, Yuan
Martini, Dylan J.
Nazha, Bassel
Brown, Jacqueline T.
Russler, Greta
Yantorni, Lauren Beth
Caulfield, Sarah
Master, Viraj A.
Carthon, Bradley Curtis
Kucuk, Omer
Bilen, Mehmet Asim
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA
[3] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16570
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)
    Kao, Chester
    George, Daniel J.
    Zhang, Tian
    ONCOLOGIST, 2021, 26 (03): : E508 - E511
  • [3] Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC)
    Kinsey, Emily
    Brown, Landon
    Kao, Chester
    Healy, Patrick
    Harrison, Michael
    McNamara, Megan
    Armstrong, Andrew
    Ramalingham, Sundhar
    George, Daniel
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
    Ebrahim, Hedyeh
    Meza, Luis A.
    Dizman, Nazli
    Barragan-Carrillo, Regina
    Li, Xiaochen
    Llamas-Quitiquit, Marian
    Hsu, Joann
    Zengin, Zeynep Busra
    Castro, Daniela V.
    Mercier, Benjamin
    Zugman, Miguel
    Jaime-Casas, Salvador
    Chehrazi-Raffle, Alex
    Trent, Jeffrey M.
    Lee, Peter P.
    Takahashi, Motomichi
    Dorff, Tanya B.
    Caporaso, Gregory
    Lee, Keehoon
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 543 - 543
  • [6] Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Castro, Daniela V.
    Mercier, Benjamin D.
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Li, Xiaochen
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Tripathi, Abhishek
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 460 - 460
  • [7] Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo)
    Zahoor, Haris
    Barata, Pedro C.
    Jia, Xuefei
    Hobbs, Brian P.
    Martin, Allison
    Allman, Kimberly D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC).
    Xu-Vuillard, Alexandre
    Jouinot, Anne
    Pudlarz, Thomas
    Blanchet, Benoit
    Huillard, Olivier
    Joly, Charlotte
    Tournigand, Christophe
    Oudard, Stephane
    Medioni, Jacques
    Vano, Yann-Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
    Gul, Anita
    Shah, Neil J.
    Mantia, Charlene
    Hammers, Hans J.
    Ornstein, Moshe Chaim
    McDermott, David F.
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345